Skip to main content
Renier Brentjens, MD, Oncology, New York, NY, Roswell Park Comprehensive Cancer Center

RenierJBrentjensMD

Oncology New York, NY

Hematologic Oncology

Associate Professor, Medicine, Weill Cornell Medical College

Dr. Brentjens is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Brentjens' full profile

Already have an account?

Summary

  • Dr. Renier Brentjens is an oncologist in Buffalo, NY and is affiliated with Roswell Park Comprehensive Cancer Center.

    Dr. Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed a residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). As a medical oncology fellow during his training at MSKCC, Dr. Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T-cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T-cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr. Brentjens became the principal investigator of his own laboratory. As a PI, Dr. Brentjens successfully translated these studies to the clinical setting treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T-cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T-cells” currently being translated to the clinical setting as second-generation CAR modified T-cell clinical trials. Additionally, work in the Brentjens’ lab has expanded this CAR technology to target additional tumor antigens expressed on other malignancies including solid tumors.

    Dr. Brentjens also speaks multiple languages, including Dutch.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1998 - 2002
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 1996 - 1998
  • University at Buffalo School of Medicine
    University at Buffalo School of MedicineClass of 1996

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1998 - 2023
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • New York Magazine: Top Doctors Castle Connolly, 2014
  • America's Top Doctors Castle Connolly, 2014
  • Top Doctors: New York Metro Area Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
    Renier J. Brentjens, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL
    Renier J. Brentjens, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management
    Renier J. Brentjens, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL “Armored” CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Tr... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Expert Discussion and Guidance on New Advances, Clinical Opportunities, and Current Challenges in Treating Adults with Ph-Negative Acute Lymphoblastic Leukemia 
    60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

  • How Durable Are CAR T-cell Therapies?
    How Durable Are CAR T-cell Therapies?March 1st, 2018
  • Anti-CD19 CAR T-cell Therapy Induces Significant Remission Rates in B-cell ALL
    Anti-CD19 CAR T-cell Therapy Induces Significant Remission Rates in B-cell ALLSeptember 19th, 2016
  • Researchers Develop ‘Armored’ CAR-T with Potential Against Solid Tumors
    Researchers Develop ‘Armored’ CAR-T with Potential Against Solid TumorsAugust 16th, 2018
  • Join now to see all

Grant Support

  • Adoptive Immunotherapy Of Cancer With IL-12 Secreting Tumor-Targeted T CellsNational Cancer Institute2009–2012
  • Genetic Targeting Of T Cells To B Cell MalignanciesNational Cancer Institute2003–2005

Professional Memberships

Other Languages

  • Dutch

Hospital Affiliations